Italia markets close in 3 hours 45 minutes

Bullfrog AI Holdings, Inc. (BFRG)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,9800-0,4100 (-17,15%)
Alla chiusura: 04:00PM EDT
2,0619 +0,08 (+4,14%)
Dopo ore: 07:51PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform

    Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable

  • GlobeNewswire

    BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma

    BullFrog AI’s Patented Drug BF-223 Demonstrates Anti-Cancer Activity Against Glioblastoma in Established Animal ModelGAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the an

  • GlobeNewswire

    BullFrog AI Founder and CEO Vin Singh to Present Company Overview at BioFuture 2023

    GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a presentation at BioFuture 2023 (Oct. 4-6, 2023) on the Company’s recent partnerships, revenue and growth strategy, and portfoli